AzTrials
AzTrials

RecoveryBOLT_PartBNCT06986356

Spoonable - Overnight Recovery

A study testing Test product: Yoghurt in people with Recovery and Muscle Function, run by Northumbria University at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The key research objective is to examine the effects of a high protein spoonable yoghurt on overnight recovery of muscle function, 12 hours following an exercise session in 18-45-year-old males and females, compared to a control group receiving flavoured waterbased placebo jelly. Read more about this study

Who is it for?
Ages 18 to 45 yearsHealthy volunteers can take part
Conditions the study is for
Recovery, Muscle Function, Muscle Soreness
What is being tested?
Test product: Yoghurt
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
26 participants
Where
1 siteUnited Kingdom
Study dates
11 Feb 2025to 30 Jun 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age ≥ 18 and ≤ 45 years
  • Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2
  • Written informed consent
  • Willingness and ability to comply with the protocol in the opinion of the Investigator
  • Judged by the Investigator to be in good health as assessed by a health screening questionnaire
  • Currently identifies as the same biological sex as at birth

Who cannot join

  • Any known ongoing medical condition that interferes significantly with absorption and digestion and/or gastrointestinal (GI) function (e.g. inflammatory bowel disease, gastroesophageal reflux disease, celiac disease, diaphragmatic hernia or diaphragmatic surgery, gastric ulcer, gastritis, gall bladder problems, pancreatitis, GI cancer, oesophageal and/or gastric surgery), in opinion of the investigator.
  • Known musculoskeletal or soft tissue injury
  • Known cardiovascular disease, disease related to the immune system and/or the respiratory system
  • Known renal or hepatic failure or known thyroid dysfunction
  • Known Diabetes Mellitus type I or type II, insulin resistance or metabolic syndrome
  • Any ongoing cancer (except for basal cell carcinoma) and/ or cancer treatment
Show all 19Show fewer
  • Known anaemia or low haemoglobin or low iron status
  • Any known bleeding disorder or reaction to withdrawal of blood samples
  • Use of oral and systemic use of prokinetics, laxatives, antidiarrheals, anticoagulants within 2 weeks prior to screening
  • Use of systemic antibiotics within 4 weeks prior to screening
  • Any known allergies or intolerances to ingredients of the study product, i.e. cow's milk allergies, lactose intolerance
  • Adherence to a strict dietary regime (e.g. vegetarian/ vegan/ paleo/ketogenic/intermittent fasting/ high protein diet (>1.6 g/kg body weight/day) or a weight loss program)
  • Use of any nutritional supplements or additional protein supplements or nutritional support within 4 weeks prior to screening
  • Falling below or exceeding the classification of Tier 1 or Tier 2 (McKay et al 2022, IJSPP. 17, 317-331). Ranging from minimum of meeting WHO guidelines for physical activity up to training ~3 times per week and local level representation in a sport.
  • Known pregnancy and/or lactation
  • Current smoking or stopped smoking for <1 month prior to screening (except for incidental smoking of ≤3 cigarettes/cigars/pipes per week on average in the last month)
  • Average alcohol use of >21 glasses* per week for men or >14 glasses per week for women (on average during the last 6 months) or drug/ medicine abuse in opinion of the investigator
  • Participation in any other clinical study with investigational or marketed products concomitantly or within 4 weeks before screening.
  • Major medical or surgical event requiring hospitalization within the preceding 3 months and/or scheduled in the period of study participation relevant in the opinion of the Investigator

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Northumbria University

    Newcastle upon Tyne

Other trials in United Kingdom

About this study

Official title: The Effects of a Commercially Available High Protein Spoonable on Overnight Recovery From Exercise Training in 18-45 Year-old Male and Females

The key research objective is to examine the effects of a high protein spoonable yoghurt on overnight recovery of muscle function, 12 hours following an exercise session in 18-45-year-old males and females, compared to a control group receiving flavoured waterbased placebo jelly. An additional aim of the study is to explore the effects of the test product vs placebo on muscle function, readiness to exercise and performance in a repeat bout of exercise training at 24 hours following initial exercise training.

Read the detailed description

This study is a single-blind, randomised, parallel group design. It involves six visits to the laboratory in total; Visit 1) pre-screening and consent; visit 2) questionnaires, anthropometrics, and familiarisation; Visit 3) baseline measures; Visit 4) exercise intervention (exercise session 1); Visit 5) post-exercise morning measures, and Visit 6) exercise intervention (exercise session 2). Participants will be randomised into one of two groups that will receive the following;

  1. Test product: High protein spoonable yoghurt (1 serving = 45 g protein comprising 3 yoghurt pots totalling 480 g) (Danone Nutricia).
  2. Control product 2: flavoured water-based placebo jelly (1 serving = 0 g protein comprising 3 jelly pots totalling 480 g).

A follow-up communication via telephone will be conducted within 7 days of completion of the final session to ensure there are no adverse effects of participation.

A detailed overview of the research activity that will take place in each session is provided below:

Visit 1: Pre-screening Volunteers will receive information on the study, and they will be familiarised with the requirements for participation and provide written informed consent. Subjects will be requested to complete 3-day food and exercise diaries, comprising of 1 weekend day, 1 rest day, and 1 exercise day within a week of the trial. This will be handed in on Visit 2. Subjects' body height, body mass, body composition, and BMI will be measured.

Visit 2: Familiarisation with the dependent measures and exercise training Volunteers will refrain from physical activity and alcohol consumption 24 hours before each visit and caffeine 12 hours before each visit. Study staff will review physical activity and food diary questionnaires and if eligibility criteria are met, volunteers will continue the trial. Measure of volunteers' body mass, stature and body composition will then be recorded. Next, volunteers will be familiarised with the dependent measures and exercise training session that will be conducted.

Visit 3: Baseline Measures Volunteers will report to the laboratory in the PM in a fed (2-3 hours post prandial) and hydrated state, where baseline measurements of all dependent variables will be taken. Which will include muscle soreness via a visual analogue scale, muscle pain pressure threshold via algometry. Measures of muscle function including Counter Movement Jump (CMJ), Reactive Strength Index (RSI) and Isometric Maximal Voluntary Contraction (iMVC). A venous blood sample will be taken to measure creatine kinase and high sensitivity C-reactive protein.

Following this, volunteers will receive standardised meals for the day of the exercise trial. Standardised meals will provide:

  • Total energy (kcals) = BMR (derived via Harris-Benedict) x 1.5 (PAL). Assuming participants will be largely sedentary apart from the exercise session.
  • Protein 1g/kg body weight for both groups.
  • Carbohydrate - Provide 50% of total energy
  • Fat - Remainder of total energy.

Participants will keep their habitual physical activity pattern between visits but not exceeding 4 exercise sessions per week (pro-rata), of which not more than 2 sessions of light resistance exercise sessions can be completed. Any exercise outside of the study will be recorded. Volunteers will be asked to refrain from any strenuous exercise 24 h prior to the first visit and for the duration of the subsequent trial visits (except for that required during the study). Volunteers will record any deviations from the standardised meal plan in a food compliance diary throughout.

Visit 4: First exercise training session Volunteers should consume breakfast before ~8 AM, lunch ~12 PM, and dinner at ~4 PM. Volunteers will attend the study site in the evening, scheduled at least 2 hours after dinner. Study staff will receive completed food compliance diary from volunteers. Volunteers will be asked to complete all dependent measures. This will be followed by the exercise training consisting of an initial warm up, a repeated sprint cycling challenge followed by an exercise circuit that will consist of intermittent high intensity exercises (detailed below) for a period likely to extend approximately 40 minutes. The session will be similar to a high intensity exercise class and the number of repetitions will be recorded in each time window to compare between Visit 4 and 6. Volunteers will wear a heart rate monitor throughout to measure peak and mean heart rate. Immediately after, measures of the participant's lactate concentration and their perceived exertion for the session followed by a further lactate sample at 15 mins. Volunteers will then complete all dependent variables and consume the test product or control product.

The exercise protocol is detailed below and will be repeated in visit 6. Warm up

  • Static exercise bike 5 minutes at 1.5 W per Kg Body mass
  • Standardised dynamic warm up (~5 minutes of walking lunges, squats \& mobility) Cycle Ergometer Repeated Sprint
  • 10 x 6s Lode Bike sprints with 30 s (active) recovery Circuit Training 5 rounds with a 30s 1:1 work rest ratio.
  • Kettlebell Thrusters (bilateral)
  • Squat Jumps (set height from plyometric box)
  • Kettlebell Walking Lunge (bilateral) • Kettlebell Swing (single)
  • Kettlebell bent-over row
  • Sled push 40 m
  • Sled pull 40 m
  • Farmers walks (bilateral kettlebell) Total time ~60 minutes Notes
  • Kettlebell weight to be selected at familiarisation and used throughout (likely ~10-20% BM)
  • Sled Row/pull will be a % of BW (TBC - likely 50% BM)

Visit 5: 12-hour overnight recovery following exercise training session 1 The participant will have a standardised breakfast at home ~7 AM and attend the laboratory ~ 2 h after. Participants will attend the study site at ~9 AM. Study staff will receive completed food compliance and study product intake diaries following exercise training 1 session (visit 4). Participants will be asked to complete a Recovery Questionnaire and the Sleep Quality Questionnaire. Participants will complete muscle soreness and pain measures. Study staff will measure volunteers' body mass and draw a blood sample. Next, volunteers will complete all dependent variables. Volunteers will consume a final serving of the study or placebo product in the laboratory when all measures are completed. After the visit volunteers will consume the provided lunch and dinner at home, at ~12PM and ~4PM, respectively.

Visit 6: 24-hour return to training readiness and performance following exercise training session 1 Physiological and performance measures pre- and post-exercise training session 2). Participants will attend the laboratory at least 2 hours after dinner (~18:00). Study staff will receive completed food compliance diary from volunteers between visit 4 and visit 6. Volunteers will be asked to complete the Recovery, Readiness to Exercise, and muscle soreness questionnaires. Study staff will measure volunteers' body mass and draw a blood sample. Then, volunteers will complete all dependent variables. After 10-15 minutes rest, volunteers will complete a second exercise training session, which will be identical to visit 4), wearing a heart rate monitor. Immediately after exercise training session 2, blood lactate concentration will be measured, followed by a further sample at 15 minutes and rate their perceived exertion. Lastly, after these measures volunteers will repeat dependent measures of muscle soreness/pain and muscle function.

Being tested
Test product: Yoghurt, Placebo
Medical subject headings
Myalgia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Test product: YoghurtDietary supplement

    High protein spoonable yoghurt

  • PlaceboDietary supplement

    Placebo Jelly

Study groups in NCT06986356
Study groupRoleWhat they receive
Test Product: YoghurtExperimentalHigh protein commercially available spoonable yoghurt (1 serving = 45 g protein comprising 3 yoghurt pots totalling 480 g) (Danone Nutricia).
Receives: Dietary Supplement: Test product: Yoghurt
Control Product: Placebo (Jelly)Placebo comparatorflavoured water-based placebo jelly (1 serving = 0 g protein comprising 3 jelly pots totalling 480 g).
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Muscle Function (Maximal voluntary contraction)

    The change from baseline in muscle function (measured via quadriceps maximum voluntary contraction; MVC) 12 hours after exercise session 1. This measurement reflect the ability for the intervention group to recovery faster or have less decrements in function. MVC will be assessed with a bespoke dynamometer (three efforts will be performed).

    Measured: Testing will occur over a two week period (from visit 2-6).This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

  2. Muscle Function (Jump Height)

    The change from baseline in muscle function (assessed by vertical jump height) 12 h after exercise session 1. This measurement reflect the ability for the intervention group to recovery faster or have less decrements in function. Vertical jump height will be assessed by a countermovement jump (CMJ).

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

  3. Muscle Function (Reactive Strength Index)

    The change from baseline in muscle function (assessed by reactive strength index; RSI) 12 h after exercise session 1. This measurement reflect the ability for the intervention group to recovery faster or have less decrements in function. RSI will be assessed by three drop jumps (average height and ground contact time [cm/m, %change]).

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

Secondary outcomes (17)
  1. Muscle Function (MVC 24 h post)

    The change from baseline in muscle function (measured via quadriceps maximum voluntary contraction; MVC) 24 h after exercise session 1. This measurement reflect the ability for the intervention group to recovery faster or have less decrements in function. MVC will be assessed with a bespoke dynamometer (three efforts will be performed).

    Measured: Testing will occur over a two week period (from visit 2-6).This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

  2. Muscle Function (Jump Height 24 h post)

    The change from baseline in muscle function (assessed by vertical jump height) 24 h after exercise session 1. This measurement reflect the ability for the intervention group to recovery faster or have less decrements in function. Vertical jump height will be assessed by a countermovement jump (CMJ).

    Measured: Testing will occur over a two week period (from visit 2-6).This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

  3. Muscle Function (RSI 24 h post)

    The change from baseline in muscle function (assessed by reactive strength index; RSI) 24 h after exercise session 1. This measurement reflect the ability for the intervention group to recovery faster or have less decrements in function. RSI will be assessed by three drop jumps (average height and ground contact time [cm/m, %change]).

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

  4. Perceived Recovery

    The change from baseline in perceived recovery [score] assessed by a recovery questionnaire across the experimental period post-exercise training session 1, between groups

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before exercise session 2 (visit 6).

  5. Subjective Muscle Soreness

    The change in subjective pain as assessed by a visual analogue scale (0 - 200mm scale, with extremes either end, 0 referring to no pain at all, 200 referring to extreme pain) over time between groups.

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

  6. Muscle Pain Pressure

    The change in pain pressure threshold using algometry of the quadriceps, from baseline and during the time course of the study.

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

  7. Sprint Performance (PPO)

    The change in repeated sprint cycle performance (peak power output; PPO, measured by watts), between the two groups.

    Measured: Testing for this measure will occur 48 hour period (two consecutive evening exercise sessions). This measure will be assessed during exercise session 1 (visit 4) and session 2 (visit 6).

  8. Sprint Performance (av. PO)

    The change in repeated sprint cycle performance (mean; average, power output, measured by watts), between the two groups

    Measured: Testing for this measure will occur 48 hour period (two consecutive evening exercise sessions). This measure will be assessed during exercise session 1 (visit 4) and session 2 (visit 6).

  9. Sprint Performance (fatigue index)

    The change in repeated sprint cycle performance (fatigue index, quantified by percentage decrease between repetitions of sprints), between the two groups

    Measured: Testing for this measure will occur 48 hour period (two consecutive evening exercise sessions). This measure will be assessed during exercise session 1 (visit 4) and session 2 (visit 6).

  10. Readiness to Train

    The change from baseline in perceived readiness to train assessed by the Return to Readiness Questionnaire [visual analogue scale] at 24 hours post-exercise training session 1, between the groups. The scale is 0-100mm, where 0 refers to 'not at all ready to train' and 100 refers to 'extremely ready to train'.

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).

  11. Marker of muscle damage (CK)

    The change from baseline over time between groups for muscle damage (serum creatine kinase (CK) [IU/L]).

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before exercise session 2 (visit 6).

  12. Marker of inflammation (hs-CRP)

    The change from baseline over time between groups for inflammation (serum C-reactive protein (hsCRP) [mg/L]).

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before exercise session 2 (visit 6).

  13. Other performance parameters (peak HR)

    The changes in performance parameters during exercise sessions 1 and 2, variables include peak heart rate [BPM] during exercise training session 1 and 2.

    Measured: Testing for this measure will occur 48 hour period (two consecutive evening exercise sessions). This measure will be assessed during exercise session 1 (visit 4) and session 2 (visit 6).

  14. Other performance parameters (mean HR)

    The changes in performance parameters during exercise sessions 1 and 2, variables include mean heart rate [BPM] during exercise training session 1 and 2.

    Measured: Testing for this measure will occur 48 hour period (two consecutive evening exercise sessions). This measure will be assessed during exercise session 1 (visit 4) and session 2 (visit 6).

  15. Other performance parameters (RPE)

    The changes in other performance parameters during exercise sessions 1 and 2 such as exercise session rating of perceived exertion (RPE). The scale used will be the Borg (6-20) RPE scale, where 6 refers to 'no exertion' and 20 refers to 'maximal exertion'.

    Measured: Testing for this measure will occur 48 hour period (two consecutive evening exercise sessions). This measure will be assessed during exercise session 1 (visit 4) and session 2 (visit 6).

  16. Other performance parameters (lactate)

    The changes in other performance parameters during exercise sessions 1 and 2, such as pre and post-exercise lactate (immediately post and 15 mins-post).

    Measured: Testing for this measure will occur 48 hour period (two consecutive evening exercise sessions). This measure will be assessed during exercise session 1 (visit 4) and session 2 (visit 6).

  17. Perceived Sleep Questionnaire

    The change from baseline in perceived sleep [score] assessed by a sleep questionnaire across the experimental period post-exercise training session 1, between groups. The score is 1-5, where 1 refers to a 'very poor' quality of sleep and 5 refers to 'very good' quality of sleep.

    Measured: Testing will occur over a two week period (from visit 2-6). This measure will be taken at baseline (visit 3), before exercise session 1 (visit 4) and 12 hours after exercise session 1 (visit 5).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 May 2025
  2. Study start11 Feb 2025
  3. Primary completion13 Jun 2025
  4. Study completion30 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06986356
Sponsor's protocol ID
BOLT_PartB_7943
Acronym
BOLT_PartB
Status last verified
Apr 2026
First submitted
25 Oct 2024
Last updated
9 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Test product: Yoghurt in people with Recovery and Muscle Function, run by Northumbria University at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Muscle Function (Maximal voluntary contraction) (time frame: Testing will occur over a two week period (from visit 2-6).This measure will be taken at baseline (visit 3), before and after exercise session 1 (visit 4), 12 hours after exercise session 1 (visit 5) and before and after exercise session 2 (visit 6).). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in